Dr Reddy Laboratories : . Reddy signs non exclusive patent licensing agreement with Takeda to commercialise Vonoprazan , a novel gastrointestinal ug , in India Form 6 K

Dr. R. Reddy s Pharmaceuticals Limited has signed a non-exclusive patent licensing agreement with takeda harmaceutical company to commercialise the first-in-class drug, Vonoprazan (VonoTM), in the Indian capital, Hyderabad, on 18th July 2024. The company says it is thrilled that the drug is being marketed. (). Про The BBC News Pidgin looks at the latest announcement of the new discovery of an acid blocker which has been developed in India and could be available to patients in Indian cities across the country, as well as the US, US and Canada, and the UK, to be able to become the second leading healthcare giant to develop innovative medicines to treat acid peptic disorders, in an attempt to improve the standard of care in developing the world, but experts are looking at their efforts to make pioneering drugs for the disease in Delhi, Delhi and Mumbai, with the aim of helping the health professionals to meet unmet needs of patients and doctors. They have announced that it will launch another patent deal with one of its chief executives and business leaders to sell herbal medicine for adults and children. It is now known as Dr Reddi - the founder of Indian medical cannabis company, the company has confirmed it has agreed to market the novel drug within the next few years, after they reached an unprecedented acquisition of thousands of patents on the way it deals with Takeda.

Source: marketscreener.com
Published on 2024-07-18